Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 35 Results

Title
Intervention Indication Therapeutic Area Year Actions
Bempegaldesleukin in combination with nivolumab for previously untreated unresectable or metastatic melanoma Bempegaldesleukin (NKTR-214; BMS-986321; NEKTAR) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2022 View  |  Download
Nivolumab (Opdivo) + Ipilimumab (Yervoy) for metastatic colorectal cancer patients with deficient DNA mismatch repair mechanism (dMMR) or high microsatellite instability (MSI-H) Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Colon cancer Gastrointestinal Cancer 2017 View  |  Download
Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy) Nivolumab (Opdivo; BMS-936558; ONO-4538) Melanoma Skin Cancer 2017 View  |  Download
Nivolumab (Opdivo) for Oesophageal Cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab (Opdivo) for the treatment of Hepatocellular Carcinoma Nivolumab (Opdivo; BMS-936558; ONO-4538) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Nivolumab (Opdivo) in combination with platinum Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Head and neck cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3) Melanoma Skin Cancer 2019 View  |  Download
Nivolumab for adjuvant and neoadjuvant treatment of localised renal cell carcinoma Nivolumab (Opdivo; BMS-936558; ONO-4538) Renal cell carcinoma (RCC) Renal Cancer 2021 View  |  Download
Nivolumab for adjuvant treatment of stage IB-IIIA non-small cell lung cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
1 2 3 4
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications